Glenmark Receive Regulatory Approval for Treatment of COVID-19

Glenmark Receive Regulatory Approval for Treatment of COVID-19. Indian Government has given approval to Glenmark India for Treatment of COVID-19. Now Glenmark will start work for Covid 19.

  1. Manufacturing and marketing approval granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India
  2. The approval’s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation
  3. Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days
  4. Clinical improvement noted across age groups 20 to >90 years, including in patients with co-morbid conditions like diabetes and heart disease suffering from mild to moderate COVID-19
  5. Glenmark to market the antiviral under the brand name ‘FabiFluĀ®’
Glenmark Receive Regulatory Approval for Treatment of COVID-19

Source:

Glenmark Pharmaceuticals Ltd

Reference:

  1. https://rdif.ru/Eng_fullNews/5224/
  2. Furtuta Y et al. Antiviral Res. 2013;100(2):446-54.
  3. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
  4. Cai Q et al. Engineering (Beijing), 2020;10.1016/j.eng.2020.03.007
  5. Chen C et al. MedRxiv. 2020 Jan 1